Moses Vaporization: Is Use of Moses 2.0 in Holmium Laser Ablation of the Prostate More Efficient

Description

To determine if use of Moses 2.0 results in improved ablation efficiency during holmium laser vaporization of the prostate. To determine if use of Moses 2.0 results in less char, improved visibility, and improved hemostasis in prostate vaporization.

Conditions

Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Talk to us

Study Overview

On this page

Study Details

Study overview

To determine if use of Moses 2.0 results in improved ablation efficiency during holmium laser vaporization of the prostate. To determine if use of Moses 2.0 results in less char, improved visibility, and improved hemostasis in prostate vaporization.

Moses Vaporization: Is Use of Moses 2.0 in Holmium Laser Ablation of the Prostate More Efficient

Moses Vaporization: Is Use of Moses 2.0 in Holmium Laser Ablation of the Prostate More Efficient

Condition
Benign Prostatic Hyperplasia
Intervention / Treatment

-

Contacts and Locations

Kansas City

University of Kansas Medical Center, Kansas City, Kansas, United States, 66104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients \> 18 years of age
  • * Patients with bothersome lower urinary tract symptoms who opt for surgical management
  • * Prostate size 60g or less
  • * Current use of anticoagulation or antiplatelet agent Aspirin 81 use is okay and can be continued through the study
  • * Bleeding diathesis
  • * AUA symptom score \< 9
  • * Current urinary retention
  • * Known diagnosis of prostate cancer
  • * Known diagnosis of neurogenic bladder

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Kansas Medical Center,

Donald Neff, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center

Study Record Dates

2026-01-01